GSK and SK Bioscience start late-stage trial of Covid-19 vaccine

GlaxoSmithKline has started the late-stage trial of its Covid-19 vaccine candidate with South Korean firm SK Bioscience (Andy Buchanan/PA)

GlaxoSmithKline (GSK) and South Korean pharmaceutical firm SK Bioscience have started a Phase 3 trial of their Covid-19 vaccine combination.

GSK told the stock market on Tuesday that the advance follows “positive” interim results in the Phase 1 and 2 studies.